Healthcare >> CEO Interviews >> November 1, 2002
PETER CHAMBRE joined Cambridge Antibody Technology Group Plc as
Chief Executive Officer in April 2002. Previously, he was Chief
Operating Officer at Celera Genomics Group and, prior to this,
held the position of CEO at Bespak Plc, the drug delivery group.
Mr. Chambre has considerable experience of senior management
roles, both in the UK and the US, where he led these companies in
their development toward the biopharmaceutical market. He has
also held positions at Bain & Company, the strategy consultancy,
and Unilever Plc. Profile
Technology Group?
Mr. Chambre: Cambridge Antibody Technology is a developer of
human antibody-based therapeutics. We were founded
